

## Prior authorization and notification list

### Humana Dual Fully Integrated H2875-001 (Virginia)

### Humana Dual Fully Integrated H2875-003 (Virginia)

**Effective Date:** 01/01/2026

**Revision Date:** 04/29/2026

We have updated our prior authorization and notification list for Humana Dual Fully Integrated (health maintenance organization Dual Eligible Special Needs Plan [HMO D-SNP]) Virginia plans.

Please note the term “prior authorization” (preauthorization, precertification), when used in this communication, is defined as a process through which the healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.

The list details medications (i.e., medications that are delivered in the provider’s office, clinic, outpatient or home setting) that require prior authorization before being provided or administered. Services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS). According to the guidelines, all medical care, services, supplies and equipment must be medically necessary. You can review Medicare coverage guidelines [on the CMS website](#).

To view Humana’s Medical and Pharmacy Coverage Policies, please visit [Humana's Medical and Pharmacy Coverage Policies website](#).

Investigational and experimental procedures and devices usually are not covered benefits. Please consult the patient’s Evidence of Coverage or contact Humana for confirmation of coverage.

Please note that certain services may not be covered under the member’s plan.

### Important notes

**Humana Medicare Advantage (MA) HMO:** The full list of prior authorization requirements applies to patients with Humana MA HMO and HMO point-of-service (HMO POS) coverage. Healthcare providers who participate in an independent practice association (IPA) or other risk network with delegated services are subject to the prior authorization list (PAL) and should refer to their IPA or risk network for guidance on processing their requests. Exclusions may change, so please refer to [Humana's provider website](#) for the most up-to-date information.

**All Humana MA plans:** For procedures or services that are investigational or experimental (or that may have limited benefit coverage), or to learn if Humana will pay for a service, you can request an advanced coverage



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

determination (ACD) on behalf of the patient [prior](#) to providing the service. You may be contacted if additional information is needed.

ACDs for medications on the list can be initiated by submitting a fax or phone request: Submit by phone at 866-461-7273 (TTY: 711), Monday – Friday, 8 a.m. – 11 p.m., Eastern time, or by fax to 888-447-3430.

To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment. Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment. To ensure appropriate claim payment, please include the modifier based on Humana's Medicare Advantage Payment Policy (CP2023011), which can be found on [Humana's claims payment policies website](#), or include medical records with evidence that the member is in an active course of treatment.

**Additional information related to step therapy for Medicare Part B medications:**

Humana's Medicare Part B Step Therapy Preferred Drug List (PDL), which includes background information about the program and a comprehensive list of preferred and nonpreferred medications, is available at [Humana's provider prior authorization notification lists website](#).

Some step therapy strategies for Medicare Advantage prescription drug plans may require a trial of a preferred medication across different benefits, such as Medicare Part B and Part D. Details regarding these cross-benefit strategies can be found on Humana's Part B Step Therapy PDL, which is available on [Humana's provider prior authorization notification lists website](#).

Humana's Part B Step Therapy PDL should be reviewed in conjunction with Humana's coverage policies, which are accessible on Humana's [Medical and Pharmacy Coverage Policies website](#).

The designation of preferred status does not guarantee exemption from step therapy requirements. Please refer to the specific criteria contained in our coverage criteria policies, which is available on Humana's [Medical and Pharmacy Coverage Policies website](#). Affected medications are noted with a step therapy indicator on the Medicare PAL at [Humana's provider prior authorization notification lists website](#).

If providers do not stock a preferred medication, they may be able to obtain the preferred medication from a pharmacy (e.g., a pharmacy can ship the medication to the office). Please review our list of specialty and mail-order pharmacies at [Humana's mail-order webpage](#) to select a pharmacy that can provide the medication. A full list of pharmacies also is available on the [pharmacy finder tool](#).

If you have questions, please call us at 800-457-4708 (TTY: 711), daily, 8 a.m. – 8 p.m., Eastern time. However, please note that our automated phone system may answer your call during weekends and holidays from April 1 to Sept. 30. Please leave your name and phone number and we'll call you back by the end of the next business day. For 24-hour service, please visit [Humana's website](#).



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

Not obtaining prior authorization for a service could result in financial penalties for the practice and reduced benefits for the patient based on the healthcare provider's contract and the patient's Evidence of Coverage. Services or medications provided without prior authorization may be subject to retrospective medical necessity review. We recommend that an individual practitioner making a specific request for services or medications verify benefits and prior authorization requirements with Humana prior to providing services.

**Information required for a prior authorization request or notification may include, but is not limited to, the following:**

- Patient name, date of birth and Humana member ID number
- Date of actual service or hospital admission
- Healthcare Common Procedure Coding System (HCPCS) code(s) and diagnosis codes (primary and secondary) (up to a maximum of 6 per authorization request)
- Service location
  - Inpatient (acute hospital, skilled nursing or hospice)
  - Outpatient (telehealth, office, home, off-campus outpatient hospital, on-campus outpatient hospital or ambulatory surgery center)
- Tax Identification Number (TIN), National Provider Identifier (NPI) of facility where service is being rendered, and TIN and NPI number of the provider performing the service
- Caller/requester name and phone number and attending provider's phone number
- Relevant clinical information

Submitting all relevant clinical information at the time of the request will help expedite determination. If additional clinical information is required, a Humana representative will request the specific information needed to complete the authorization process.

**How to request prior authorization:**

Except where noted in the list below, prior authorization for medications may be initiated in one of 3 ways:

- Online: [CoverMyMeds](#)
- Phone number: 866-461-7273 (TTY: 711), Monday – Friday, 8 a.m. – 11 p.m., Eastern time
- Fax number: 888-447-3430 (Request forms are available on Humana's [prior authorization for professionally administered drugs website](#).)

The list below is subject to change with notification and may be modified throughout the year for additions of new-to-market medications or step therapy requirements for medications without notification by United States Postal Service mail.



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Abecma intravenous suspension ††	idecabtagene vicleucel ††	Q2055
Abraxane ** ‡	paclitaxel-nab ** ‡	J9264
Actemra IV **	tocilizumab **	J3262
Adakveo	crizanlizumab-tmca	J0791
Adcetris	brentuximab vedotin	J9042
Adstiladrin	nadofaragene firadenovec-vncg	J9029
Aduhelm	aducanumab-avwa	J0172
Adzynma	ADAMTS13, recombinant-krhn	J7171
Akynzeo IV	fosnetupitant and palonosetron	J1454
Aldurazyme	laronidase	J1931
Alimta ‡	pemetrexed ‡	J9305
Alyglo **	immune globulin intravenous, human-stwk **	J1552
Alymsys **	bevacizumab-maly **	Q5126
Amondys-45	casimersen	J1426
Amtagvi †† ‡	lifileucel †† ‡	C9399, J3490, J9999
Amvuttra	vutrisiran	J0225
Anktiva	nogapendekin alfa inbakicept-pmIn	J9028
Aphexda	motixafortide	J2277
Aralast NP ** ‡	alpha 1-proteinase inhibitor ** ‡	J0256
Aranesp **	darbepoetin alfa **	J0881
Asceniv **	immune globulin **	J1554



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Asparlas	calaspargase pegol-mknl	J9118
Aucatzyl ††	obecabtagene autoleucl ††	Q2058
Aukelso * ** ‡	denosumab-kyqq * ** ‡	Q5161
Avastin ** (Auth only required for Oncology/Chemo use)	bevacizumab **	J9035, C9257
Aveed	testosterone undecanoate	J3145
Avlayah * † ‡	tividenofusp alfa-eknm * † ‡	C9399, J3490, J3590
Avsola **	infliximab-axxq **	Q5121
Avtozma IV ** ‡	tocilizumab-anoh ** ‡	Q5156
Axtle ‡	pemetrexed ‡	J9292
Azedra	ibogenguane l 131	A9590
Bavencio	avelumab	J9023
Beizray	docetaxel-albumin	J9174
Beleodaq	belinostat	J9032
Belrapzo ‡	bendamustine hydrochloride ‡	J9036
Bendamustine (Apotex)	bendamustine hydrochloride	J9058
Bendamustine (Baxter)	bendamustine hydrochloride	J9059
Bendamustine ‡	bendamustine hydrochloride ‡	J9036
Bendeka	bendamustine hydrochloride	J9034
Benlysta	belimumab	J0490
Beovu **	brovacizumab-dbll **	J0179
Berinerter **	C1 esterase inhibitor **	J0597



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Besponsa	inotuzumab ozogamicin	J9229
Bildyos ** ‡	denosumab-nxxp ** ‡	Q5162
Bilprevda ** ‡	denosumab-nxxp ** ‡	Q5162
Bivigam **	immune globulin **	J1556
Bizengri	zenocutuzumab-zbco	J9382
Bkemv IV **	eculizumab-aeeb **	Q5152
Blenrep ‡	belantamab mafodotin-blmf ‡	C9399, J3490, J3590, J9999
Blincyto	blinatumomab	J9039
Bomynta ** ‡	denosumab-bnht ** ‡	Q5158
bortezomib (Dr. Reddy's)	bortezomib	J9046
bortezomib (Fresenius kabi)	bortezomib	J9048
bortezomib (Hospira)	bortezomib	J9049
bortezomib (Maia)	bortezomib	J9051
bortezomib ‡	bortezomib ‡	J9041
Boruzu	bortezomib	J9054
Bosaya * ** ‡	denosumab-kyqq * ** ‡	Q5161
Botox	onabotulinumtoxinA	J0585
Breyanzi †† ‡	lisocabtagene maraleucel †† ‡	Q2054
Brineura	cerliponase alfa	J0567
Briumvi **	ublituximab-xiiy **	J2329
Byooviz **	ranibizumab-nuna intravitreal solution **	Q5124



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Carvykti ††	ciltacabtagene autoleucl ††	Q2056
Casgevvy ††	exagamglogene autotemcel ††	J3392
Cerezyme **	imiglucerase **	J1786
Cimzia **	certolizumab pegol **	J0717
Cinqair	reslizumab	J2786
Cinryze **	C1 esterase inhibitor (human) **	J0598
Columvi	glofitamab-gxbm	J9286
Conexence ** ‡	denosumab-bnht ** ‡	Q5158
Cosela	trilaciclib	J1448
Cosentyx IV **	secukinumab **	J3247
Crysvita	burosumab-twza	J0584
Cutaquig **	immune globulin **	J1551
Cuvitru **	immune globulin **	J1555
Cyramza	ramucirumab	J9308
Danyelza	naxitamab-gqgk	J9348
Darzalex	daratumumab	J9145
Darzalex Faspro	daratumumab and hyaluronidase-fihj	J9144
Datroway	datopotamab deruxtecan	J9011
Dawnzera ** ‡	donidalorsen ** ‡	C9399, J3490
Daxxify	daxibotulinumtoxinA-lanm	J0589
Defitelio ‡	defibrotide sodium ‡	C9399, J3490



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Docivyx	docetaxel	J9172
Doxil	doxorubicin HCL liposome injection	Q2050
Durysta	bimatoprost implant	J7351
Dysport	abobotulinumtoxin A	J0586
Elahere	mirvetuximab soravtansine-gynx	J9063
Elaprase	idursulfase	J1743
ElELYso	taliglucerase alfa	J3060
Elevidys	delandistrogene moxeparvovec-rokl	J1413
Elfabrio IV	pegunigalsidase alfa-iwxj	J2508
Elrexfio	elranatamab-bcmm	J1323
Elzonris	tagraxofusp-erzs	J9269
Empaveli ‡	pegcetacoplan ‡	C9399, J3490
Empliciti	elotuzumab	J9176
Emrelis IV	telisotuzumab vedotin-tllv	J9326
Encelto	revakinagene taroretcel-lwey	J3403
Enhertu	fam-trastuzumab deruxtecan-nxki	J9358
Enjaymo	sutimlimab-jome	J1302
Enoby ** ‡	denosumab-qbde ** ‡	C9399, J3490, J3590, J9999
Enspryng ‡	satralizumab-mwge ‡	C9399, J3590, J3490
Entyvio IV **	vedolizumab **	J3380
Epkinly	epcoritamab-bysp	J9321



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Epogen ** ‡	epoetin alfa ** ‡	J0885
Epysqli IV **	eculizumab-aagh **	Q5151
Erbitux	cetuximab	J9055
Erwinase ‡	crisantaspase ‡	J9019
Euflexxa **	sodium hyaluronate **	J7323
Evenity **	romosozumab-aqqg **	J3111
Evkeeza **	evinacumab-dgnb **	J1305
Exdensur ** ‡	depemokimab-ulaa ** ‡	C9399, J3490, J3590
Exondys 51	eteplirsen	J1428
Eylea **	aflibercept **	J0178
Eylea HD **	aflibercept **	J0177
Fabrazyme	agalsidase beta	J0180
Fasenra	benralizumab	J0517
Faslodex	fulvestrant	J9395
Feraheme **	ferumoxytol **	Q0138
Firazyr ** ‡	icatibant ** ‡	J1744
Flebogamma DIF ‡	immune globulin ‡	J1572
Folotyng ‡	pralatrexate ‡	J9307
Fulphila	pegfilgrastim-jmdb	Q5108
fulvestrant (Fresenius kabi)	fulvestrant	J9394
fulvestrant (Teva)	fulvestrant	J9393



\* New preauthorization requirement

‡ New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
<b>Fyarro</b>	sirolimus protein-bound particles for injectable suspension	<b>J9331</b>
<b>Fylnetra **</b>	pegfilgrastim-pbbk **	<b>Q5130</b>
<b>GamaSTAN ‡</b>	immune globulin ‡	<b>J1460, J1560</b>
<b>GamaSTAN S/D ‡</b>	immune globulin ‡	<b>J1460, J1560</b>
<b>Gamifant</b>	emapalumab-lzsg	<b>J9210</b>
<b>Gammagard ‡</b>	immune globulin ‡	<b>J1569</b>
<b>Gammagard ERC ‡</b>	immune globulin, human ‡	<b>J1566, J1569</b>
<b>Gammagard S/D ‡</b>	immune globulin ‡	<b>J1566</b>
<b>Gammaked ‡</b>	immune globulin ‡	<b>J1561</b>
<b>Gammaplex **</b>	immune globulin **	<b>J1557</b>
<b>Gamunex-C ‡</b>	immune globulin ‡	<b>J1561</b>
<b>Gazyva</b>	obinutuzumab	<b>J9301</b>
<b>Gel-One **</b>	sodium hyaluronate **	<b>J7326</b>
<b>Gelsyn-3 **</b>	sodium hyaluronate **	<b>J7328</b>
<b>Genvisc 850 **</b>	sodium hyaluronate **	<b>J7320</b>
<b>Givlaari</b>	givosiran	<b>J0223</b>
<b>Glassia **</b>	alpha 1-proteinase inhibitor **	<b>J0257</b>
<b>Granix **</b>	tbo-filgrastim **	<b>J1447</b>
<b>Haegarda</b>	c1 esterase inhibitor subcutaneous	<b>J0599</b>
<b>Herceptin (IV) **</b>	trastuzumab **	<b>J9355</b>



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
<b>Herceptin Hylecta **</b>	trastuzumab and hyaluronidase-oysk **	<b>J9356</b>
<b>Hercessi IV **</b>	trastuzumab-strf **	<b>Q5146</b>
<b>Herzuma **</b>	trastuzumab-pkrb **	<b>Q5113</b>
<b>Hizentra</b>	immune globulin	<b>J1559</b>
<b>Hyalgan ** ‡</b>	sodium hyaluronate ** ‡	<b>J7321</b>
<b>Hymovis ** ‡</b>	sodium hyaluronate ** ‡	<b>J7322</b>
<b>Hymovis ONE ** ‡</b>	HYALURONATE ** ‡	<b>C9399, J3490</b>
<b>Hyqvia **</b>	immune globulin **	<b>J1575</b>
<b>iDose TR 75mcg intracameral implant</b>	travoprost intracameral implant	<b>J7355</b>
<b>Ilaris</b>	canakinumab	<b>J0638</b>
<b>Ilumya **</b>	tildrakizumab-asmn **	<b>J3245</b>
<b>Iluvien</b>	fluocinolone acetonide	<b>J7313</b>
<b>Imaavy **</b>	nipocalimab-aahu **	<b>J9256</b>
<b>Imdelltra</b>	tarlatamab-dlle	<b>J9026</b>
<b>Imfinzi **</b>	durvalumab **	<b>J9173</b>
<b>Imjudo **</b>	tremelimumab-actl **	<b>J9347</b>
<b>Imlygic</b>	talimogene laherparepvec	<b>J9325</b>
<b>Imuldosa IV ** ‡</b>	ustekinumab-srlf ** ‡	<b>Q5098</b>
<b>Inflectra</b>	infliximab-dyyb	<b>Q5103</b>
<b>Infliximab</b>	infliximab	<b>J1745</b>



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Injectafer **	ferric carboxymaltose **	J1439
Inlexzo intravesical system	gemcitabine	J9183
Istodax	romidepsin	J9319
Itvisma ‡	onasemnogene abeparvovec-brve ‡	C9309, J3490, J3590
Ixempra	ixabepilone	J9207
Izervay	avacincaptad pegol intravitreal solution	J2782
Jelmyto ‡	mitomycin ‡	J9281
Jemperli	dostarlimab-gxly	J9272
Jevtana	cabazitaxel	J9043
Jobevne **	bevacizumab-nwgd **	Q5160
Jubbonti ‡	denosumab-bbdz ‡	Q5136
Kadcyla	ado-trastuzumab emtansine	J9354
Kalbitor **	ecallantide **	J1290
Kanjinti	trastuzumab-anns	Q5117
Kanuma	sebelipase alfa	J2840
Kebilidi †† ‡	eladocagene exuparvovec-tneq †† ‡	C9399, J3490, J3590
Keytruda **	pembrolizumab **	J9271
Keytruda Qlex **	pembrolizumab and berahyaluronidase alfa-pmph **	J9277
Khazory	levoleucovorin	J0642
Kimmtrak	tebentafusp-tebn	J9274



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Kisunla	donanemab-azbt	J0175
Korsuva	difelikefalin	J0879
Krystexxa	pegloticase	J2507
Kymriah ††	tisagenlecleucel ††	Q2042
Kyprolis	carfilzomib	J9047
Kyxata	carboplatin	J9278
Lamzede	velmanase alfa-tycv	J0217
Ianreotide (Cipla)	Ianreotide	J1932
Ianreotide ‡	Ianreotide ‡	J1930
Lantidra †† ‡	donislecel-jujn †† ‡	C9399, J3490, J3590
Lemtrada **	alemtuzumab **	J0202
Lenmeldy ††	atidarsagene autotemcel ††	J3391
Leqembi	Iecanemab-irmb	J0174
Leqembi Iqlik ‡	Iecanemab-irmb ‡	C9399, J3490, J3590
Leqvio **	inclisiran **	J1306
Leukine	sargramostim	J2820
Levoleucovorin ‡	levoleucovorin calcium ‡	J0641
Libtayo	cemiplimab-rwlc	J9119
Loargys ‡	pegzilarginase-nbln ‡	C9399, J3490, J3590
Loqtorzi	toripalimab-tpzi	J3263
Lucentis **	ranibizumab **	J2778



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Lumizyme	alglucosidase alfa	J0221
Lunsumio ‡	mosunetuzumab-axgb ‡	J9350
Lunsumio Velo ‡	mosunetuzumab-axgb ‡	J9350
Lutathera **	lutetium Lu 177 dotatate **	A9513
Luxturna	voretigene neparvovec-rzyl	J3398
Lyfgenia ††	lovotibeglogene autotemcel ††	J3394
Lymphir *	denileukin diftitox-cxdl *	J9161
Lynozytic	linvoseltamab-gcpt	J9601
Margenza	margetuximab-cmkb	J9353
Mepsevii	vestronidase alfa-vjbn	J3397
Mircera	methoxy polyethylene glycol - epoetin beta	J0888
Monjuvi	tafasitamab-cxix	J9349
Monoferric **	ferric derisomaltose **	J1437
Mozobil ‡	plerixafor ‡	J2562
Mvasi	bevacizumab-awwb	Q5107
Mylotarg	gemtuzumab ozogamicin	J9203
Myobloc	rimabotulinumtoxinB	J0587
Naglazyme	galsulfase	J1458
Neulasta ‡	pegfilgrastim ‡	J2506
Neulasta Onpro ‡	pegfilgrastim ‡	J2506
Neupogen **	filgrastim **	J1442



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Nexviazyme	avalglucosidase alfa-ngpt	J0219
Ngenla ‡	somatrogon-ghla ‡	C9399, J3490, J3590
Niktimvo IV	axatilimab-csfr	J9038
Nivestym **	filgrastim-aafi **	Q5110
Nplate	romiplostim	J2802
Nucala	mepolizumab	J2182
Nulibry	fosdenopterin	J1809
Nypozi **	filgrastim-txid **	Q5148
Nyvepria **	pegfilgrastim-apgf **	Q5122
Ocrevus	ocrelizumab	J2350
Ocrevus Zunovo	ocrelizumab and hyaluronidase-oscq	J2351
Octagam	immune globulin	J1568
Ogivri **	trastuzumab-dkst **	Q5114
Omisirge †† ‡	omidubicel-only †† ‡	C9399, J3490, J3590
OmvoH IV ** ‡	mirikizumab-mrkz ** ‡	J2267
Onapgo SQ Cartridge ‡	apomorphine hydrochloride ‡	C9399, J3490
Oncaspar	pegaspargase	J9266
Onivyde	irinotecan liposome injection	J9205
Onpattro	patisiran	J0222
Ontruzant **	trastuzumab-dttb **	Q5112
Opdivo **	nivolumab **	J9299



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
<b>Opdivo Qvantig</b>	nivolumab hyaluronidase-nvhy	<b>J9289</b>
<b>Opdualag</b>	nivolumab and relatlimab-rmbw injection	<b>J9298</b>
<b>Orencia IV **</b>	abatacept **	<b>J0129</b>
<b>Osenvelt ** ‡</b>	denosumab-bmwo ** ‡	<b>Q5157</b>
<b>Ospomyv ** ‡</b>	denosumab-dssb ** ‡	<b>Q5159</b>
<b>Otulfli IV</b>	ustekinumab-aaaz	<b>Q9999</b>
<b>Oxlumo</b>	lumasiran	<b>J0224</b>
<b>Ozurdex</b>	dexamethasone intravitreal implant	<b>J7312</b>
<b>paclitaxel protein-bound ** ‡</b>	paclitaxel protein-bound ** ‡	<b>J9264</b>
<b>Padcev</b>	enfortumab vedotin-ejfv	<b>J9177</b>
<b>Palynziq ‡</b>	pegvaliase-pqpz ‡	<b>C9399, J3490, J3590</b>
<b>Panhematin</b>	hemin	<b>J1640</b>
<b>Panzyga **</b>	immune globulin **	<b>J1576</b>
<b>Papzimeos</b>	zopapogene imadenovec-drba	<b>J3404</b>
<b>Pavblu **</b>	aflibercept-ayyh **	<b>Q5147</b>
<b>Pedmark IV solution</b>	sodium thiosulfate	<b>J0208</b>
<b>Pemetrexed</b>	premetrexed	<b>J9305</b>
<b>Pemetrexed (Accord)</b>	pemetrexed	<b>J9296</b>
<b>Pemetrexed (Bluepoint)</b>	pemetrexed	<b>J9322</b>
<b>Pemetrexed (Sandoz)</b>	pemetrexed	<b>J9297</b>
<b>Pemetrexed (Teva)</b>	pemetrexed	<b>J9314</b>



\* New preauthorization requirement

‡ New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
pemetrexed disodium (Hospira)	pemetrexed disodium	J9294
pemetrexed ditromethamine	pemetrexed ditromethamine	J9323
Pemfexy	pemetrexed injection	J9304
Pemrydi RTU	pemetrexed	J9324
Perjeta	pertuzumab	J9306
Phesgo	pertuzumab, trastuzumab, and hyaluronidase-zzxf	J9316
Piasky **	crovalimab-akkz **	J1307
plerixafor ‡	plerixafor ‡	J2562
Pluvicto	lutetium Lu 177 vipivotide tetraxetan	A9607
Polivy	polatuzumab vedotin-piiq	J9309
Pombiliti	cipaglucosidase alfa-atga	J1203
Portrazza	necitumumab	J9295
Poteligeo	mogamulizumab-kpkc	J9204
pralatrexate IV ‡	pralatrexate ‡	J9307
Prevymis IV ‡	letermovir ‡	C9399, J3490
Prialt	ziconotide	J2278
Privigen	immune globulin	J1459
Procrit ‡	epoetin alfa ‡	J0885
Prolastin-C ** ‡	alpha 1-proteinase inhibitor ** ‡	J0256
Prolia	denosumab	J0897
Provenge	sipuleucel-T	Q2043



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Pyzchiva IV **	ustekinumab-ttwe **	Q9997
Qalsody	tofersen	J1304
Qivigy ** ‡	immune globulin intravenous, human-kthm ** ‡	C9399, J3490, J3590, J1599
Qutenza	capsaicin/skin cleanser	J7336
Radicava	edaravone	J1301
Reblozyl **	luspatercept-aamt **	J0896
Releuko **	filgrastim-ayow injection **	Q5125
Remicade	infliximab	J1745
Remodulin ‡	treprostinil (injection) ‡	J3285
Renflexis **	infliximab-abda **	Q5104
Retacrit	epoetin alfa-epbx	Q5106
Rethymic †† ‡	allogeneic processed thymus tissue- agdc †† ‡	C9399, J3490, J3590
Riabni **	rituximab-arrx **	Q5123
Rituxan Hycela **	rituximab; hyaluronidase human **	J9311
Rituxan IV **	rituximab **	J9312
Rolvedon **	eflapegrastim-xnst **	J1449
romidepsin	romidepsin	J9318
Ruconest **	C1 esterase inhibitor **	J0596
Ruxience **	rituximab-pvvr **	Q5119
Rybrevant Faspro ‡	amivantamab and hyaluronidase-lpuj ‡	C9399, J3490, J3590, J9999



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
<b>Rybrevent IV</b>	amivantamab-vmjw	<b>J9061</b>
<b>Rylaze</b>	asparaginase erwinia chrysanthemi (recombinant)-rywn	<b>J9021</b>
<b>Ryoncil ††</b>	remestemcel-L-rknd ††	<b>J3402</b>
<b>Ryplazim</b>	plasminogen, human-tvmh	<b>J2998</b>
<b>Rystiggo **</b>	rozanolixizumab-noli **	<b>J9333</b>
<b>Rytelo IV</b>	imetelstat	<b>J0870</b>
<b>Ryzneuta **</b>	efbemalenograstim alfa-VUXW **	<b>J9361</b>
<b>Sajazir ‡</b>	icatibant ‡	<b>J1744</b>
<b>Sandostatin LAR</b>	octreotide	<b>J2353</b>
<b>Saphnelo intravenous solution</b>	anifrolumab-fnia	<b>J0491</b>
<b>Sarclisa</b>	isatuximab-irfc	<b>J9227</b>
<b>Scenesse</b>	afamelanotide	<b>J7352</b>
<b>Selarsdi IV ** ‡</b>	ustekinumab-aekn ** ‡	<b>Q9998</b>
<b>Signifor LAR</b>	pasireotide	<b>J2502</b>
<b>Simponi ARIA</b>	golimumab	<b>J1602</b>
<b>Sinuva</b>	mometasone furoate	<b>J7402</b>
<b>Skyrizi IV</b>	risankizumab-rzaa	<b>J2327</b>
<b>Skysona ††</b>	elivaldogene autotemcel ††	<b>J3387</b>
<b>Soliris **</b>	eculizumab **	<b>J1299</b>
<b>Somatuline Depot ‡</b>	lanreotide ‡	<b>J1930</b>
<b>Spevigo IV</b>	spesolimab-sbzo	<b>J1747</b>



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Spinraza	nusinersen	J2326
Starjemza IV ** ‡	ustekinumab-hmny ** ‡	C9399, J3490, J3590
Stelara IV ‡	ustekinumab ‡	J3358
Steqeyma IV **	ustekinumab-stba **	Q5099
Stimufend **	pegfilgrastim-fpgk **	Q5127
Stoboclo ** ‡	denosumab-bmwo ** ‡	Q5157
Sustol	granisetron	J1627
Susvimo **	ranibizumab **	J2779
Syfovre	pegcetacoplan	J2781
SynoJoynt **	1% sodium hyaluronate **	J7331
Synribo	omacetaxine mepesuccinate	J9262
Synvisc ** ‡	hylan G-F 20 ** ‡	J7325
Takhzyro **	lanadelumab-flyo **	J0593
Talvey	talquetamab-tgvs	J3055
Tecartus ††	brexucabtagene autoeucel ††	Q2053
Tecelra ††	afamitresgene autoleucel ††	Q2057
Tecentriq **	atezolizumab **	J9022
Tecentriq Hybreza **	atezolizumab and hyaluronidase-tqjs **	J9024
Tecvayli	teclistamab-cqyv	J9380
Tepezza	teprotumumab-trbw	J3241
Tevimbra	tislelizumab-jsgr	J9329



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Tezspire ‡	tezepelumab-ekko ‡	J2356
Tezspire subcutaneous pen injector ‡	tezepelumab-ekko ‡	J2356
Thrombate III	antithrombin III	J7197
Tivdak **	tisotumab vedotin-tftv **	J9273
Tofidence IV **	tocilizumab-bavi **	Q5133
Trazimera	trastuzumab-qyyp	Q5116
Treanda	bendamustine hydrochloride	J9033
Tremfya IV ‡	guselkumab ‡	J1628
Triluron **	sodium hyaluronate **	J7332
Trisenox	arsenic trioxide	J9017
TriVisc **	sodium hyaluronate **	J7329
Trodelyv	sacituzumab govitecan-hziy	J9317
Truxima **	rituximab-abbs **	Q5115
Tyenne IV **	tocilizumab-aazg **	Q5135
Tyruko	natalizumab-sztn	Q5134
Tysabri **	natalizumab **	J2323
Tyvaso	treprostinil (inhaled)	J7686
Tzield	teplizumab-mzwv	J9381
Udenyca ‡	pegfilgrastim-cbqv ‡	Q5111
Udenyca Autoinjector ‡	pegfilgrastim-cbqv ‡	Q5111
Udenyca Onbody ‡	pegfilgrastim-cbqv ‡	Q5111



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Ultomiris	ravulizumab-cwvz	J1303
Unituxin ‡	dinutuximab ‡	C9399, J3490
Unloxcyt *	cosibelimab-ipdl *	J9275
Uplizna **	inebilizumab-cdon **	J1823
Ustekinumab IV ** ‡	ustekinumab ** ‡	J3358
Vabysmo **	faricimab-svoa injection **	J2777
Valstar	valrubicin	J9357
Vectibix	panitumumab	J9303
Vegzelma **	bevacizumab-adcd **	Q5129
Velcade ‡	bortezomib ‡	J9041
Veopoz	pozelimab-bbfg	J9376
Viltepso	viltolarsen	J1427
Vimizim	elosulfase alfa	J1322
Visco-3 ** ‡	sodium hyaluronate ** ‡	J7321
Vivimusta	bendamustine hydrochloride	J9056
Vpriv **	velaglucerase alfa **	J3385
Vyepti **	eptinezumab-jjmr **	J3032
Vyjuvek	beremagene geperpavec-svdt	J3401
Vyloy	zolbetuximab-clzb	J1326
Vyondys 53	golodirsen	J1429
Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	J9334



\* New preauthorization requirement

‡ New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Vygart IV	efgartigimod alfa-fcab	J9332
Vyxeos	daunorubicin/cytarabine	J9153
Wainua ‡	eplontersen injection ‡	C9399, J3490
Wezlana IV **	ustekinumab-auub **	Q5138
Wyost ** ‡	denosumab-bbdz ** ‡	Q5136
Xembify	immune globulin	J1558
Xenpozyme	olipudase alfa-rpcp	J0218
Xeomin	incobotulinumtoxinA	J0588
Xgeva ** ‡	denosumab ** ‡	J0897
Xipere	triamcinolone acetonide	J3299
Xofigo	radium Ra 223 dichloride	A9606
Xolair	omalizumab	J2357
Xtrenbo ** ‡	denosumab-qbde ** ‡	C9399, J3490, J3590, J9999
Yartemlea ‡	narsoplimab-wuug ‡	C9399, J3490, J3590
Yervoy **	ipilimumab **	J9228
Yescarta ††	axicabtagene ciloleucel ††	Q2041
Yesintek IV ‡	ustekinumab-kfce ‡	Q5100
Yimmugo **	immune globulin intravenous, human - dira **	J1553
Yondelis	trabectedin	J9352
Zaltrap	ziv-aflibercept	J9400
Zarxio	filgrastim-sndz	Q5101



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

**Humana Dual Fully Integrated (HMO D-SNP) Virginia prior authorization and notification list**  
[Access the fax forms](#) to request preauthorization or provide notification.

Brand medication name	Generic medication name	Billing codes
Zemaira ‡	alpha 1-proteinase inhibitor ‡	J0256
Zepzelca	lurbinectedin	J9223
Zevalin	ibritumomab tiuxetan	A9543
Zevaskyn ††	prademagene zamikeracel ††	J3389
Ziextenzo **	pegfilgrastim-bmez **	Q5120
Ziihera	zanidatamab-hrii	J9276
Zilretta **	triamcinolone acetonide **	J3304
Zirabev	bevacizumab-bvzr	Q5118
Zoladex	goserelin acetate	J9202
Zolgensma	onasemnogene abeparvovec-xioi	J3399
Zusduri	mitomycin	J9282
Zynlonta	loncastuximab tesirine-lpyl	J9359
Zynteglo ††	betibeglogene autotemcel ††	J3393
Zynyz	retifanlimab-dlwr	J9345



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

<b>Blood-clotting Factors</b>		
<b>Brand medication name</b>	<b>Generic medication name</b>	<b>Billing codes</b>
<b>Advate †</b>	antihemophilic factor, human recombinant †	<b>J7192</b>
<b>Adynovate</b>	antihemophilic factor [recombinant], PEGylated	<b>J7207</b>
<b>Afstyla</b>	antihemophilic factor (recombinant) single chain	<b>J7210</b>
<b>Alhemo **</b>	concizumab-mtci **	<b>J7173</b>
<b>Alphanate</b>	antihemophilic factor/von Willebrand factor complex [human]	<b>J7186</b>
<b>AlphaNine SD</b>	coagulation factor IX [human]	<b>J7193</b>
<b>Alprolix</b>	coagulation factor IX [recombinant]	<b>J7201</b>
<b>Altuviio</b>	efanesoctocog alfa	<b>J7214</b>
<b>Benefix †</b>	coagulation factor IX [recombinant] †	<b>J7195</b>
<b>Beqvez</b>	fidanacogene elaparvovec-dzkt	<b>J1414</b>
<b>Coagadex</b>	coagulation factor X [human]	<b>J7175</b>
<b>Corifact</b>	factor XIII concentrate [human]	<b>J7180</b>
<b>Eloctate</b>	antihemophilic factor [recombinant], Fc fusion protein	<b>J7205</b>
<b>Esperoct</b>	antihemophilic factor (recombinant), glycopegylated-exei	<b>J7204</b>
<b>Feiba NF</b>	anti-inhibitor coagulant complex	<b>J7198</b>
<b>Hemgenix</b>	etranacogene dezaparvovec-drlb	<b>J1411</b>
<b>Hemlibra **</b>	emicizumab-kxwh **	<b>J7170</b>
<b>Hemofil M †</b>	antihemophilic factor [human] †	<b>J7190</b>
<b>Humate-P</b>	antihemophilic factor/von Willebrand factor complex [human]	<b>J7187</b>



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

<b>Blood-clotting Factors</b>		
<b>Brand medication name</b>	<b>Generic medication name</b>	<b>Billing codes</b>
<b>Hympavzi **</b>	marstacimab-hncq **	<b>J7172</b>
<b>Idelvion</b>	coagulation factor IX (recombinant)	<b>J7202</b>
<b>Ixinity</b>	coagulation factor IX [recombinant]	<b>J7213</b>
<b>Jivi</b>	antihemophilic factor (recombinant), PEGylated-aucl	<b>J7208</b>
<b>Koate-DVI ‡</b>	antihemophilic factor [human] ‡	<b>J7190</b>
<b>Kogenate FS ‡</b>	antihemophilic factor [recombinant] ‡	<b>J7192</b>
<b>Kovaltry</b>	antihemophilic factor [recombinant]	<b>J7211</b>
<b>NovoEight</b>	turoctocog alfa	<b>J7182</b>
<b>NovoSeven RT</b>	coagulation Factor VIIa, recombinant; eptacog alfa	<b>J7189</b>
<b>Nuwiq</b>	simoctocog alfa	<b>J7209</b>
<b>Obizur</b>	antihemophilic factor [recombinant], porcine sequence	<b>J7188</b>
<b>Profilnine</b>	factor IX complex	<b>J7194</b>
<b>Qfitlia ** ‡</b>	fitusiran ** ‡	<b>J7174</b>
<b>Rebinyx</b>	Coagulation Factor IX [Recombinant], GlycoPEGylated	<b>J7203</b>
<b>Recombinate ‡</b>	antihemophilic factor [recombinant] ‡	<b>J7192</b>
<b>Rixubis</b>	coagulation factor IX [recombinant]	<b>J7200</b>
<b>Roctavian</b>	valoctocogene roxaparvovec-rvox	<b>J1412</b>
<b>SevenFact intravenous solution</b>	coagulation factor VIIa (recombinant)-jncw; eptacog beta	<b>J7212</b>
<b>Tretten</b>	coagulation factor XIII A-subunit [recombinant]	<b>J7181</b>
<b>Vonvendi</b>	von Willebrand factor [recombinant]	<b>J7179</b>



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).

<b>Blood-clotting Factors</b>		
<b>Brand medication name</b>	<b>Generic medication name</b>	<b>Billing codes</b>
<b>Wilate</b>	von Willebrand factor / coagulation factor VIII complex [human]	<b>J7183</b>
<b>Xyntha ‡</b>	antihemophilic factor [recombinant] ‡	<b>J7185</b>
<b>Xyntha Solofuse ‡</b>	antihemophilic factor [recombinant] ‡	<b>J7185</b>



\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

\*\* Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to [transplant@humana.com](mailto:transplant@humana.com).